Oxaliplatin Aqvida

Oxaliplatin, the active ingredient in Oxaliplatin Aqvida, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in the treatment of certain solid tumours, most notably colorectal cancer, and is administered by healthcare professionals in hospital or oncology centre settings.

GNH USA supplies Oxaliplatin Aqvida as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Aqvida is a platinum‑based chemotherapeutic that acts on the DNA replication pathway in malignant cells. - Colorectal cancer: used in combination regimens to inhibit tumour growth and improve survival. - Gastric cancer: incorporated into multi‑drug protocols to enhance response rates. - Pancreatic cancer: added to standard chemotherapy backbones to increase disease control. - Ovarian cancer: employed in selected cases as part of combination therapy to achieve cytoreduction.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, depending on patient factors and treatment context.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhoea: loose stools that may require supportive care. - Fatigue: generalized tiredness during treatment cycles. - Thrombocytopenia: reduced platelet count increasing bleed risk.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis or bronchospasm. - Acute neurotoxicity: sudden onset of muscle cramps or dysesthesia. - Hematologic toxicity: profound neutropenia or anemia. - Hepatotoxicity: elevated liver enzymes indicating liver stress. - Renal impairment: decreased kidney function requiring monitoring.

When using Oxaliplatin Aqvida, clinicians should assess patient suitability and monitor for known risks. - Renal function: evaluate creatinine clearance before each infusion. - Hepatic function: check liver enzymes and bilirubin levels regularly. - Neuropathy monitoring: assess sensory changes before and during therapy. - Hematologic surveillance: perform complete blood counts to detect cytopenias. - Premedication: consider anti‑emetics and antihistamines as per protocol. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Oxaliplatin may interact with several concomitant medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aminoglycoside antibiotics: increased risk of nephrotoxicity. - High‑dose vitamin C: may reduce platinum‑drug cytotoxicity. - Live vaccines: immunosuppression can lead to uncontrolled infection.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): heightened bleeding risk due to thrombocytopenia. - NSAIDs: may exacerbate renal toxicity. - CYP‑inducing agents: potential impact on drug clearance, though oxaliplatin is not primarily metabolised by CYP enzymes.